UNSPSC 51433807: Cilazapril monohydrate

This classification denotes an ace inhibitor with the molecular structure C22H31N3O5.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 19KW7PI29F chemically known as (1s,9s)-9-(((s)-1-carboxy-3-phenylpropyl)amino)octahydro-10-oxo-6h-pyridazino(1,2-a)(1,2)diazepine-1-carboxylic acid 9-ethyl ester monohydrate, but more commonly known as cilazapril, which bears US NIH Compound Identifier 56329. European Medicines Agency schedules Cilazapril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06265MIG.

UNSPSC 51433807 Cilazapril monohydrate is a Commodity code representing a single pharmaceutical product line, but recent state and local procurement activity under this code shows minimal direct demand for cilazapril specifically. Instead, state and local governments solicit pharmaceuticals at the broader family and class levels when procuring medical supplies and medications for emergency services, state health agencies, and cooperative purchasing vehicles. The work actually being solicited centers on advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products supplied through authorized wholesale channels with stringent compliance requirements for manufacturing practices, drug supply chain security, expiration dating, and FDA approval. Issuing bodies include municipal fire rescue departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Tampa Fire Rescue (via the City of Tampa) and the Texas Health and Human Services Commission represent state and local users; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, structures procurement across multiple participating states and local entities.

Geographic activity centers on Texas, Florida, and Minnesota, with multistate reach through cooperative vehicles like MMCAP that serve Oregon and other participating jurisdictions. Representative recent opportunities include the City of Tampa's IFB (Solicitation 26P00188, due April 8, 2026) for advanced life support medications—labetalol, epinephrine, adenosine, and diltiazem injections and vials valued at $40,000 with a one-year initial term and renewal options, featuring a 5 percent bid discount for Small Local Business Enterprises; MMCAP's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) with a two-year contract term effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness; and the Texas HHS Commission's RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription fulfillment capabilities as a preliminary market intelligence exercise ahead of a formal RFP. No recent opportunities specifically named cilazapril monohydrate; procurement at this code tier appears limited relative to activity at higher UNSPSC family and class levels for general pharmaceutical supply.